Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

Whole exome DNA sequence analysis of Brca2 and Trp53 deficient mouse mammary gland tumours.

Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.

J Pathol. 2015 Feb 18. doi: 10.1002/path.4517. [Epub ahead of print]

PMID:
25692405
[PubMed - as supplied by publisher]
2.

Functional genetic screen identifies increased sensitivity to WEE1 inhibition in cells with defects in Fanconi Anaemia and HR pathways.

Aarts M, Bajrami I, Herrera-Abreu MT, Elliott R, Brough R, Ashworth A, Lord CJ, Turner NC.

Mol Cancer Ther. 2015 Feb 11. pii: molcanther.0845.2014. [Epub ahead of print]

PMID:
25673822
[PubMed - as supplied by publisher]
3.

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.

Rajan N, Elliott RJ, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A.

Oncotarget. 2014 Dec 15;5(23):12126-40.

PMID:
25565632
[PubMed - in process]
Free PMC Article
4.

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015 Jan 14;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.

PMID:
25341009
[PubMed - in process]
5.

DAISY: picking synthetic lethals from cancer genomes.

Ryan CJ, Lord CJ, Ashworth A.

Cancer Cell. 2014 Sep 8;26(3):306-8. doi: 10.1016/j.ccr.2014.08.008.

PMID:
25203319
[PubMed - in process]
6.

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM.

Cancer Res. 2014 Oct 15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 2014 Aug 28.

PMID:
25168481
[PubMed - indexed for MEDLINE]
7.

Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress.

McDade SS, Patel D, Moran M, Campbell J, Fenwick K, Kozarewa I, Orr NJ, Lord CJ, Ashworth AA, McCance DJ.

Nucleic Acids Res. 2014 Jun;42(10):6270-85. doi: 10.1093/nar/gku299. Epub 2014 May 13.

PMID:
24823795
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.

Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, Antonopoulos A, Fearns A, Jamal-Hanjani M, Sims D, Fenwick K, Mitsopoulos C, Gao Q, Orr N, Zvelebil M, Haslam SM, Dell A, Yarwood H, Lord CJ, Ashworth A, Isacke CM.

Cancer Discov. 2014 Mar;4(3):304-17. doi: 10.1158/2159-8290.CD-13-0287. Epub 2014 Feb 11.

PMID:
24520024
[PubMed - indexed for MEDLINE]
9.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

PMID:
24395524
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The genomic landscape of oesophagogastric junctional adenocarcinoma.

Chong IY, Cunningham D, Barber LJ, Campbell J, Chen L, Kozarewa I, Fenwick K, Assiotis I, Guettler S, Garcia-Murillas I, Awan S, Lambros M, Starling N, Wotherspoon A, Stamp G, Gonzalez-de-Castro D, Benson M, Chau I, Hulkki S, Nohadani M, Eltahir Z, Lemnrau A, Orr N, Rao S, Lord CJ, Ashworth A.

J Pathol. 2013 Nov;231(3):301-10.

PMID:
24308032
[PubMed - indexed for MEDLINE]
11.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.

Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.

PMID:
24240700
[PubMed - indexed for MEDLINE]
Free Article
12.

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Lord CJ, Ashworth A.

Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7. Review.

PMID:
24202391
[PubMed - indexed for MEDLINE]
13.

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.

Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, André F, Soria JC, Lord CJ, Ashworth A.

Oncogene. 2013 Nov 21;32(47):5377-87. doi: 10.1038/onc.2013.311. Epub 2013 Aug 12.

PMID:
23934192
[PubMed - indexed for MEDLINE]
14.

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.

Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.

PMID:
23922302
[PubMed - indexed for MEDLINE]
Free Article
15.

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Mereniuk TR, El Gendy MA, Mendes-Pereira AM, Lord CJ, Ghosh S, Foley E, Ashworth A, Weinfeld M.

Mol Cancer Ther. 2013 Oct;12(10):2135-44. doi: 10.1158/1535-7163.MCT-12-1093. Epub 2013 Jul 24.

PMID:
23883586
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.

Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A.

Clin Cancer Res. 2013 Sep 15;19(18):5003-15. doi: 10.1158/1078-0432.CCR-13-1391. Epub 2013 Jul 23.

PMID:
23881923
[PubMed - indexed for MEDLINE]
Free Article
17.

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A.

PLoS One. 2013 Apr 25;8(4):e61520. doi: 10.1371/journal.pone.0061520. Print 2013.

PMID:
23634208
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Identification of miRNA modulators to PARP inhibitor response.

Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A.

DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6.

PMID:
23570906
[PubMed - indexed for MEDLINE]
19.

Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.

Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, Bajrami I, McGonnell IM, Lord CJ, Reis RM, Hargrave D, Ashworth A, Workman P, Jones C.

Cancer Discov. 2013 May;3(5):512-9.

PMID:
23539269
[PubMed - in process]
Free PMC Article
20.

Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.

Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22. No abstract available.

PMID:
23524863
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk